Palm

Deal details

The Company is a privately held Biopharmaceuticals [biosimilar] Developer & Manufacturer, having more than 15 years of successful track record in developing and selling biosimilar pharmaceuticals worth hundreds of Millions of U.S. Dollars in end user prices. Operating from a fully equipped, cGNP certified FDA & EMA compliant, chemical & biological 7,000 Sq.M. manufacturing plant and state-of-the-art laboratories, 85 employees, 20 Ph.D's. The company developed and owns a diverse biosimilar mAbs pipeline, of which original products current market worth Billions of U.S. Dollars. Company seek to recruit $25Million implementing an aggressive growth plan leveraging its integrated development and manufacturing capabilities.